DataMEDS AI, Inc. (MEDS) vs Traws Pharma, Inc. (TRAW)

A side-by-side comparison of DataMEDS AI, Inc. and Traws Pharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — MEDS vs TRAW

growth of $100 · dividends reinvested · last 10y
MEDS -94.7% (-25.4%/yr)TRAW -100.0% (-64.2%/yr)MEDS compounded faster over this window
Log scale — wide-divergence pair
0001101001kStart $10020182020202220242026$5$0
MEDS TRAW

MEDS vs TRAW: by the numbers

  • •MEDS is the larger company ($8M vs $8M market cap).
  • •TRAW is profitable (328.67% net margin) while MEDS runs a net loss (-1100.30%).

Metrics side by side

Valuation

MetricMEDSTRAW
P/S ratio1.06N/A

Profitability

MetricMEDSTRAW
Gross margin-41.30%100.00%
Operating margin-347.91%-640.68%
Net margin-1100.30%328.67%
ROIC-439.90%N/A

Growth (annualized)

MetricMEDSTRAW
Revenue CAGR (5Y)N/A64.60%
Total return CAGR (5Y)-45.88%-64.14%

Frequently asked

Is MEDS or TRAW more profitable?
TRAW runs the higher net margin — MEDS at -1100.30% versus TRAW at 328.67%.
How have MEDS and TRAW total returns compared?
Over the past 10 years, MEDS delivered -25.43% and TRAW delivered -64.35% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.